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ALPPS

:   associating liver partition and portal vein ligation

ALT

:   alanine transaminase

AST

:   aspartate transaminase

AUC

:   area under the curve

CCC

:   cholangiocellular carcinoma

CPM

:   counts per million

GEO

:   Gene Expression Omnibus

GGT

:   gamma‐glutamyl transpeptidase

HCC

:   hepatocellular carcinoma

ICG

:   indocyanine green

ICU

:   intensive care unit

ISGLS

:   International Study Group of Liver Surgery

LD

:   liver dysfunction

LR

:   logistic regression

mCRC

:   metastatic colorectal carcinoma

miRNA

:   microRNA

NGS

:   next‐generation sequencing

NPV

:   negative predictive value

OR

:   odds ratio

POD

:   postoperative day

PPV

:   positive predictive value

pre‐OP

:   preoperatively

qPCR

:   real‐time quantitative PCR

ROC

:   receiver operator characteristic

SN

:   sensitivity

SP

:   specificity

Liver resection represents the only curative treatment in many liver malignancies. Postresectional hepatic regeneration determines the clinical outcome of patients undergoing liver resection,[1](#hep30572-bib-0001){ref-type="ref"} as insufficient hepatic regeneration after liver resection results in postoperative liver dysfunction (LD), which occurs in up to 30% of patients after major hepatic resections.[2](#hep30572-bib-0002){ref-type="ref"} Importantly, currently available treatment options for patients with postoperative LD are very limited, mostly symptomatic, and goal‐directed.[2](#hep30572-bib-0002){ref-type="ref"}, [3](#hep30572-bib-0003){ref-type="ref"} Hence, risk stratification for optimized patient selection before liver operation is key for minimizing the postoperative LD and concomitant complications. This is specifically relevant for patients suffering from extensive disease who require surgical procedures with a high risk of postoperative complications and mortality, such as the associating liver partition and portal vein ligation (ALPPS) procedure, to achieve complete tumor clearance. However, currently available markers are often expensive, time consuming, and invasive, highlighting the need for an easily assessable preoperative test to predict postoperative liver function recovery.

Emerging evidence suggests that microRNA (miRNA) signatures represent potent diagnostic, prognostic, and treatment‐response biomarkers for several diseases.[4](#hep30572-bib-0004){ref-type="ref"} As master regulators of expression of multiple genes in different tissues, miRNAs can control virtually every cellular process on a transcriptional level, including cellular development, proliferation, migration, survival, metabolism, homeostasis, and regeneration.[5](#hep30572-bib-0005){ref-type="ref"} Estimates based on computational analyses suggest that over 50% of the human transcriptome is regulated by at least one miRNA.[6](#hep30572-bib-0006){ref-type="ref"} Hence, it is not surprising that aberrant miRNA expression can have detrimental effects on signaling pathways and indeed has been implicated in a wide range of diseases.[7](#hep30572-bib-0007){ref-type="ref"}, [8](#hep30572-bib-0008){ref-type="ref"}, [9](#hep30572-bib-0009){ref-type="ref"} To date, almost 2,000 miRNAs have been identified, and some have already been validated for *in vitro* diagnosis and/or prognosis of various malignant diseases, demonstrating their potential as biomarkers in the clinic.[10](#hep30572-bib-0010){ref-type="ref"}, [11](#hep30572-bib-0011){ref-type="ref"}, [12](#hep30572-bib-0012){ref-type="ref"} Moreover, miRNAs are easily accessible from biofluids such as blood, urine, and saliva through noninvasive methods, and they exhibit high stability and relatively low complexity (e.g., no postprocessing modifications) and can be readily assessed by various methods with high specificity (SP), making them superior compared with other classes of biomarkers, including DNA, RNA, and proteins.

Thus, the aim of this study was to systematically elucidate potential differences in the profile of circulating miRNAs between patients with and without postoperative LD and poor postoperative outcome. Thus, we used next‐generation sequencing (NGS) as an unbiased systematic approach to investigate the predictive potential of miRNA profiles in plasma of a discovery cohort of patients undergoing liver resection. We identified a clinically applicable and robust combination of specific miRNAs to efficiently predict postoperative LD as well as complications before operation and verified these findings in an independent prospective validation cohort by real‐time quantitative PCR (qPCR). Importantly, within this analysis, we observed a superior prognostic performance of the established miRNA signature when compared with currently used clinical markers for prediction of postoperative LD. Ultimately, we provide exploratory data suggesting that miRNA signatures can dynamically monitor liver function recovery and might represent a very useful tool to define the most suitable time point for liver resection to avoid postoperative LD and complications.

Materials and Methods {#hep30572-sec-0002}
=====================

Details on methodology can be found within the Supporting Information for this manuscript.

Study Population {#hep30572-sec-0003}
----------------

Initially, a discovery cohort of patients was prospectively recruited starting from February 2012. Patients with hepatocellular carcinoma (HCC), cholangiocellular carcinoma (CCC), or metastatic colorectal carcinoma (mCRC) were considered eligible for inclusion. Subsequently, we validated our explorative results in a prospective cohort. Ultimately, we monitored miRNAs of interest in a subset of patients before operation as well as on postoperative day (POD) 1 and POD 5.

The present study was approved by the Institutional Ethics Committee, and written informed consent was obtained.

Definition and Classification of Postoperative LD and Complications {#hep30572-sec-0004}
-------------------------------------------------------------------

Patients were followed up for a postoperative period of 90 days. Postoperative LD was diagnosed following the criteria issued by the International Study Group of Liver Surgery (ISGLS).[13](#hep30572-bib-0013){ref-type="ref"} Accordingly, LD was defined by both abnormal values of serum bilirubin and prothrombin time on or after POD 5. Of note, in case of abnormal preoperative serum bilirubin or prothrombin time, a postoperative deviation and deterioration on 2 subsequent days after POD 5 was identified as postoperative LD. Furthermore, patients reaching normal serum bilirubin or prothrombin time values before POD 5, or who were discharged early because of good clinical performance and hence had no further blood collection, were considered as having "no LD."

For classification of patients with postoperative morbidity, the outline given by Dindo et al.[14](#hep30572-bib-0014){ref-type="ref"} was applied. Death within 90 days after operation was classified as postoperative mortality.[15](#hep30572-bib-0015){ref-type="ref"}

Measurement of Circulating miRNAs {#hep30572-sec-0005}
---------------------------------

Meticulous preparation of plasma was performed as described.[16](#hep30572-bib-0016){ref-type="ref"}

RNA Extraction and Small RNA Sequencing {#hep30572-sec-0006}
---------------------------------------

The miRNeasy Mini Kit (Qiagen, Germany) was applied to isolate total RNA, including small RNAs, from plasma. Small RNA sequencing libraries were generated using the CleanTag Small RNA Library Preparation Kit (TriLink) according to the manufacturer\'s recommendations. Sequencing was performed on an Illumina NextSeq 500, using single‐end reads with 50 cycles (Illumina). Sequencing reads in fastq format were adapter‐trimmed and quality‐checked (generation of fastQC files). Quality filtered reads (phred \> 30) were used for alignment against human mature miRNAs (miRBase version 21) using Bowtie 2. Mapped reads were cross‐checked through genome alignments (Bowtie 2, Genome Reference Consortium human genome build 37). Mature miRNA reads were counted (isomiR sequences were summarized) and normalized as counts per million (CPM) to the total number of mapped reads. CPM values were used for statistical analysis (see below). Sequencing raw and normalized data can be accessed under the record GSE123605 from the National Center for Biotechnology Information Gene Expression Omnibus (GEO).

qPCR Analysis {#hep30572-sec-0007}
-------------

qPCR analyses were performed as described.[17](#hep30572-bib-0017){ref-type="ref"} Robustness of RNA extraction, complementary DNA (cDNA) synthesis, and qPCR amplification was assessed using combinations of synthetic spike‐in controls (Exiqon, Denmark). Hemolysis was assessed using the ratios of miRNA‐23a‐3p and miRNA‐451a.[18](#hep30572-bib-0018){ref-type="ref"} Of note, no samples failed because of hemolysis or high analytical variance.

Statistical Analyses {#hep30572-sec-0008}
--------------------

Statistical analysis was based on nonparametric tests. Calculations were performed using SPSS (version 23.0; IBM Corp., Armonk, NY) and R (version 3.4.1; R Foundation, Vienna, Austria). *P* values were adjusted for multiple testing based on the false discovery rate according to the Benjamini‐Hochberg method, and *P* values \< 0.05 were considered significant. For more detail on statistical methods, refer to the [Supporting Materials and Methods](#hep30572-sup-0001){ref-type="supplementary-material"} section.

Results {#hep30572-sec-0009}
=======

Patients and Cohorts {#hep30572-sec-0010}
--------------------

A total of 48 patients with mCRC, HCC, or CCC who underwent liver resection between February 2012 and April 2016 were included in the discovery cohort. To achieve a representative cohort, 21 patients suffering from postoperative LD were matched based on basic characteristics, liver function, and extent of liver resection to 27 patients without postoperative LD (Supporting Table [S1](#hep30572-sup-0001){ref-type="supplementary-material"}). Subsequently, an additional 98 patients served as a prospective validation cohort (Table [1](#hep30572-tbl-0001){ref-type="table"}). Additionally, the perioperative dynamics of miRNAs were evaluated in a group of 7 patients undergoing regular major liver resection and a group of 8 patients undergoing ALPPS (Supporting Table [S2](#hep30572-sup-0001){ref-type="supplementary-material"}) for whom longitudinal measurements of miRNAs could be performed on the basis of repeatedly collected plasma samples.

###### 

Patient Demographics

  Parameter                      Entire Cohort (N = 154)   Evaluation Cohort (N = 48)   Validation Cohort (N = 106)   *P* Value
  ------------------------------ ------------------------- ---------------------------- ----------------------------- -----------
  Sex                                                                                   0.696                         
  Male                           106 (68.8%)               32 (66.7%)                   74 (69.8%)                    
  Female                         48 (31.2%)                16 (33.3%)                   32 (30.2%)                    
  Age (years)                    65 (22‐89)                65 (36‐89)                   65 (22‐86)                    0.838
  Hepatic resection                                                                                                   \<0.001
  Minor (\<3 segments)           55 (35.7%)                4 (8.3%)                     51 (48.1%)                    
  Major (≥3 segments)            99 (64.2%)                44 (91.7%)                   55 (51.9%)                    
  Tumor type                                                                                                          0.147
  CRCLM                          62 (40.3%)                16 (33.3%)                   46 (43.4%)                    
  HCC                            48 (31.2%)                16 (33.3%)                   32 (30.2%)                    
  CCC                            41 (26.6%)                16(33.3%)                    25 (23.6%)                    
  Other                          3 (1.9%)                  0 (0.0%)                     3 (2.8%)                      
  Cofactors                                                                                                           
  Neoadjuvant CTx                55 (35.7%)                16 (33.3%)                   39 (36.8%)                    0.053
  Steatosis (%)                  5 (0‐100)                 5 (0‐40)                     5 (0‐100)                     0.299
  Steatohepatitis                29 (18.8%)                10 (20.8%)                   19 (17.9%)                    0.341
  Fibrosis                       81 (52.6%)                19 (39.5%)                   61 (57.5%)                    0.411
  Cirrhosis                      20 (13.0%)                4 (8.3%)                     16 (15.1%)                    0.614
  Intraoperative RBCs            13 (8.4%)                 7 (14.6%)                    6 (5.7%)                      0.061
  Preoperative parameters                                                                                             
  PDR (%)                        20.7 (7.6‐40.0)           20.0 (9.9‐34.8)              20.9 (7.6‐40.0)               0.629
  R15 (%)                        5.0 (0.3‐32.0)            5.0 (0.5‐22.7)               4.8 (0.3‐32.0)                0.674
  Platelets (×10^3^/µL)          229 (78‐492)              236 (86‐492)                 227 (78‐470)                  0.535
  SB (mg/dL)                     0.57 (0.15‐3.77)          0.57 (0.15‐3.17)             0.57 (0.16‐3.77)              0.515
  PT (%)                         100 (40‐150)              102 (40‐137)                 99 (45‐150)                   0.355
  AP (U/L)                       95 (43‐707)               104 (49‐707)                 90 (43‐418)                   0.190
  GGT (U/L)                      74 (13‐576)               32 (18‐1,576)                73 (13‐1,335)                 0.120
  AST (U/L)                      31 (14‐224)               33 (17‐224)                  31 (14‐175)                   0.347
  ALT (U/L)                      31 (9‐318)                84 (9‐318)                   28 (8‐196)                    0.279
  Albumin (g/L)                  41.8 (30.9‐49.6)          42.6 (31.5‐47.3)             41.0 (30.9‐49.6)              0.175
  Morbidity                                                                                                           0.354
  No morbidity                   77 (50.0%)                21 (43.8%)                   56 (52.8%)                    
  Grade I                        14 (9.1%)                 4 (8.3%)                     10 (9.4%)                     
  Grade II                       29 (18.8%)                7 (14.6%)                    22 (20.8%)                    
  Grade III                      18 (11.6%)                9 (18.8%)                    9 (8.5%)                      
  Grade IV                       8 (5.1%)                  2 (4.1%)                     6 (5.7%)                      
  Grade V                        8 (5.2%)                  5 (10.4%)                    3 (2.8%)                      
  LD ISGLS                                                                                                            \<0.001
  No LD                          124 (81.1%)               27 (56.3%)                   98 (92.4%)                    
  ISGLS A                        7 (4.5%)                  5 (10.4%)                    2 (1.9%)                      
  ISGLS B                        8 (5.2%)                  4 (8.3%)                     4 (3.8%)                      
  ISGLS C                        14 (9.1%)                 12 (25.0%)                   2 (1.9%)                      
  Postoperative stay                                                                                                  
  ICU (days)                     1 (0‐25)                  1 (0‐15)                     1 (0‐25)                      0.190
  Total hospitalization (days)   9 (3‐117)                 11 (4‐50)                    9 (3‐117)                     0.096

Abbreviations: AP, alkaline phosphatase; CRCLM, colorectal cancer liver metastases; CTx, chemotherapy; PDR, plasma disappearance rate; PT, prothrombin time; R15, retention rate at 15 minutes; RBC, red blood cell; SB, serum bilirubin.
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Establishing the Predictive miRNA Panel for LD After Operation in the Discovery Cohort {#hep30572-sec-0011}
--------------------------------------------------------------------------------------

For initial identification of miRNAs associated with postoperative LD, we aimed for an unbiased systematic approach using NGS. miRNAs, small nuclear RNAs, small nucleolar RNAs, transfer RNAs, and Y RNAs were identified in the data set (see Supporting Fig. [S1](#hep30572-sup-0001){ref-type="supplementary-material"}; NGS data were submitted to GEO and can be downloaded using the accession number GSE123605). Subsequently, we focused on miRNA, given the above‐mentioned benefits, and analyzed miRNA profiles in the plasma of all patients within the discovery cohort before operation to determine if miRNA profiles differ between patients who develop LD and those without delayed hepatic recovery. With an average of 3 million miRNA reads per sample, we detected a total of 554 miRNAs across all analyzed plasma samples. To identify potential biomarker candidates, cutoffs for plasma abundance (average log~2~ CPM \[logCPM\] \> 5), effect size (fold change \> 1.3), and significance level (*P* \< 0.2) were implied. As depicted in Fig. [1](#hep30572-fig-0001){ref-type="fig"}A, a set of 19 miRNAs remained in the analysis, of which 12 were up‐regulated (red) and 7 were down‐regulated (blue) in the pre‐OP plasma of patients with LD. A clustered expression heat map, comparing expression of these miRNAs in patients with and without LD, is depicted in Fig. [1](#hep30572-fig-0001){ref-type="fig"}B.

![Differences in presurgical microRNA patterns in patients undergoing liver resection. (A) Volcano plot of differentially regulated microRNAs in presurgical plasma of patients with LD. To identify biomarker candidates, cutoffs for plasma concentration (average logCPM \> 5), effect size (fold change \> 1.3), and significance level (raw *P* \< 0.2) were implied. A set of 19 microRNAs, of which 12 were up‐regulated (red) and 7 were down‐regulated (blue), was identified. (B) Expression heat map of regulated miRNAs in plasma of patients (miR‐wise *z* score of log~2~ \[CPM + 1\]); red indicates higher expression than the mean and blue indicates lower expression than the mean, according to the legend at the bottom.](HEP-69-2636-g001){#hep30572-fig-0001}

Subsequently, we evaluated the analytical variability between NGS and qPCR‐based miRNA detection and calculated the relative logarithmic differences between two miRNAs to form self‐normalizing miRNA pairs, thus circumventing the need for a reference miRNA. Six of the top miRNAs, and consequently 15 miRNA pairs, were considered for this analysis. We observed high concordance between data sets (NGS vs. qPCR‐based miRNAs) as illustrated in Supporting Fig. [S2](#hep30572-sup-0001){ref-type="supplementary-material"}. The importance of miRNA pairs for achieving excellent predictive performance of negative postoperative outcomes was analyzed using random forest modelling (Fig. [2](#hep30572-fig-0002){ref-type="fig"}A). Two top‐ranked miRNA pairs (151a‐5p_192‐5p, 122‐5p_151a‐5p) were identified with significant pre‐OP differences between individuals developing LD and controls (Fig. [2](#hep30572-fig-0002){ref-type="fig"}B). The diagnostic performance of a multivariate model as measured by receiver operator characteristic (ROC) analysis estimated an area under the curve (AUC) of 0.66 for miRNA pair 122‐5p/151a‐5p (Fig. [2](#hep30572-fig-0002){ref-type="fig"}C), 0.75 for miRNA pair 151a‐5p/192‐5p (Fig. [2](#hep30572-fig-0002){ref-type="fig"}D), and 0.76 for a logistic regression (LR) model using the combination of both miRNA pairs (Fig. [2](#hep30572-fig-0002){ref-type="fig"}E).

![Analysis of the diagnostic performance of miRNA pairs to predict LD. (A) Importance of miRNA pairs in a random forest classification model (the most important ones are at the top with highest mean decrease accuracy). (B) Distribution of ratios measured by qPCR in the discovery cohort for miR151a‐5p/192‐5p (boxplots and *P* values from two‐sided Wilcoxon rank‐sum test) and for miR122‐5p/151a‐5p. (C) ROC curves for an LR model including miR122‐5p/151a‐5p in the discovery cohort (results from leave‐one‐out cross‐validation are in gray). (D) An LR model including miR151‐5p/192‐5p and (E) an LR model including both miRNA pairs. The performance is described by the AUC, and whether the classification deviates significantly from the random assignment (AUC = 0.5) is indicated by the *P* value. The percentage of true postoperative LD on predicted controls and predicted LD were analyzed for both model‐defined cutoffs: *P* \> 0.59 and *P* \> 0.68 (F).](HEP-69-2636-g002){#hep30572-fig-0002}

Next, two clinically useful cutoffs were defined to predict postoperative LD. Accordingly, a low‐stringency cutoff to identify patients who could undergo liver resection with very low risk (cut‐off *P* \> 0.59) as well as a stringent cutoff to identify patients who should be optimized before surgery or not undergo liver resection (cut‐off *P* \> 0.68) were defined (see Supporting Table [S3](#hep30572-sup-0001){ref-type="supplementary-material"}). For both cutoffs, predictions were found to be significantly associated with postoperative LD (*P* = 0.00045 and *P* = 0.00054, respectively; Fig. [2](#hep30572-fig-0002){ref-type="fig"}F).

Validation of the Discovered miRNA Ratios in an Independent Validation Cohort {#hep30572-sec-0012}
-----------------------------------------------------------------------------

To confirm the clinical utility of our miRNA ratios, we next validated the predictive performance of the two miRNA pairs in an independent prospective validation cohort consisting of 98 patients, 90 without and 8 with postoperative LD, reflecting the natural postsurgical LD incidence of approximately 10%‐20%. The diagnostic performance of a multivariate model as measured by ROC analysis showed an AUC of 0.69 for the two miRNA pairs (Fig. [3](#hep30572-fig-0003){ref-type="fig"}A). Further, we validated that the two cutoffs were able to predict postoperative LD for cut‐off *P* \> 0.59 with *P* = 0.011 (Fig. [3](#hep30572-fig-0003){ref-type="fig"}A) and for cut‐off *P* \> 0.68 with *P* = 0.032 (Fig. [3](#hep30572-fig-0003){ref-type="fig"}A), respectively.

![Validation of predictive performance of the top two miRNA ratios in an independent cohort and analyses of the complete data set. miRNAs were analyzed by qPCR in 98 subjects of which 8 (8.1%) experienced the adverse outcome postsurgery. (A) The predictive performance of the previously defined multivariate logistic prediction models was validated using ROC analyses. The performance is described by the AUC and whether the classification deviates significantly from the random assignment (AUC = 0.5) is indicated by the *P* value. The percentage of true postoperative LD on predicted controls and predicted LD were analyzed for both model‐defined cutoffs: *P* \> 0.59 and *P* \> 0.68. The two cutoffs were further analyzed for their performance to predict postoperative LD in the entire cohort (B). Performance was described using SN, SP, PPV, NPV, and the OR, which is the ratio of odds of suffering from postoperative LD associated with a positive test result compared with a negative test result. The low‐stringency cutoff (*P* = 0.59) yielded PPV and NPV values of 0.70 and 0.89, respectively, whereas the stringent cutoff (*P* = 0.68) resulted in a PPV of 0.83, with an NPV of 0.85 (B). This means that 83% of the patients who tested positive suffered from postoperative LD, whereas 85% who tested negative did not suffer from postoperative LD. In contrast, 15% who tested negative did in fact suffer from postoperative LD. The ORs for an adverse event were 18.66 (*P* \< 0.0001) and infinite (*P* \< 0.0001), respectively. ROC curve analysis was performed for the microRNA model to compare its performance against that of standard liver function parameters (B). ORs for other adverse postoperative outcomes were analyzed for both model cutoffs: severe morbidity (C) and mortality (D). Postoperative ICU stay (E) and hospitalization (F) were significantly prolonged in our predicted risk groups (boxplots are shown without outliers; *P* values from two‐sided Wilcoxon rank‐sum test). Abbreviations: PDR, plasma disappearance rate; R15, retention rate at 15 minutes.](HEP-69-2636-g003){#hep30572-fig-0003}

Comparison of the Discovered miRNA Ratios to Other Predictors for Postoperative LD {#hep30572-sec-0013}
----------------------------------------------------------------------------------

Next, we evaluated the performance of the miRNA‐based prediction model in the combined data set (N = 146) to increase the power of our analyses. First, to assess independence of the identified miRNA pairs to predict postoperative LD from other known markers of liver damage and function, as well as from clinical parameters, multivariate LR analysis was performed for both pairs independently. Strikingly, both miRNA pairs remained significant on multivariate LR analysis (Table [2](#hep30572-tbl-0002){ref-type="table"}).

###### 

Univariate and Multivariate LR Models

  Variables                                                       Levels (Unit)     n                                            Coeff        *P* Value
  --------------------------------------------------------------- ----------------- -------------------------------------------- ------------ --------------
  Univariate LR models                                                                                                                        
  **122‐5p/151‐5p**                                               **∆Cq**           **56**                                       **1.098**    ***0.0025***
  **151a‐5p/192‐5p**                                              **∆Cq**           **56**                                       **−1.643**   ***0.0035***
  Sex                                                             Male vs. female   56                                           −1.609       ***0.0459***
  Age                                                             years             56                                           0.0015       0.6731
  Extent of hepatic resection                                     Major vs. minor   56                                           1.695        0.1261
  Tumor type                                                      HCC vs. CCC       56                                           0.223        0.8128
                                                                  CRCLM vs. CCC                                                  −18.180      0.9934
  Steatosis (\>10%)                                               Yes vs. no        56                                           −0.594       0.4493
  Liver cirrhosis                                                 Yes vs. no        56                                           0.669        0.4638
  PDR                                                             \%                56                                           0.000        0.9938
  R15                                                             \%                56                                           0.067        0.2624
  SB                                                              mg/dL             56                                           0.001        0.9981
  AP                                                              U/L               56                                           0.006        ***0.0841***
  **AST**                                                         **U/L**           **56**                                       **0.017**    ***0.0377***
  **ALT**                                                         **U/L**           **56**                                       **0.015**    ***0.0941***
  **GGT**                                                         **U/L**           **56**                                       **0.004**    ***0.0662***
  **Albumin**                                                     **g/L**           **56**                                       **−0.170**   ***0.0895***
  Platelet count                                                  ×10^3^/µL         56                                           0.003        0.6140
  PT                                                              \%                56                                           −0.016       0.3850
  Change of platelet count                                        POD 1 / pre‐OP    56                                           1.198        0.2120
  Change of PT                                                    POD 1 / pre‐OP    56                                           0.421        0.8473
  Change of albumin                                               POD 1 / pre‐OP    50[\*](#hep30572-note-0005){ref-type="fn"}   −0.955       0.8769
  Multivariate LR models[†](#hep30572-note-0006){ref-type="fn"}                                                                               
  Intercept                                                       ---               56                                           6.107        0.3693
  **122‐5p/151‐5p**                                               **∆Cq**                                                        **1.023**    ***0.0081***
  Sex                                                             Male vs. female                                                −1.523       0.2081
  AP                                                              U/L                                                            −0.019       0.2762
  AST                                                             U/L                                                            −0.003       0.8796
  ALT                                                             U/L                                                            −0.016       0.5406
  GGT                                                             U/L                                                            0.007        0.2979
  Albumin                                                         g/L                                                            −0.211       0.1733
  Intercept                                                       ---               56                                           37.646       ***0.0061***
  **151a‐5p/192‐5p**                                              **∆Cq**                                                        **6.622**    ***0.0001***
  Sex                                                             Male vs. female                                                −4.140       ***0.0188***
  AP                                                              U/L                                                            −0.025       0.3829
  AST                                                             U/L                                                            −0.201       0.0233
  ALT                                                             U/L                                                            0.086        0.1018
  GGT                                                             U/L                                                            0.004        0.7193
  **Albumin**                                                     **g/L**                                                        **−1.090**   ***0.0022***

*P* = the *P*value from Wald test indicating significant influence in the LR model; n = number of patients included in the model with no missing values in any of the selected parameter.

Of note, albumin measurement on POD 1 was missing in 6 patients.

Only variables with *P* \< 0.1 in the univariate LR model were included (indicated in italics), all VIFs between explanatory variables \< 4; *P* values \< 0.05 are indicated in bold.

Abbreviations: ΔCq, delta quantification cycle; AP, alkaline phosphatase; Coeff, coefficient of the respective variable in the LR model; CRCLM, colorectal cancer liver metastases; PDR, plasma disappearance rate; PT, prothrombin time; R15, retention rate at 15 minutes; SB, serum bilirubin; VIF, variance inflation factor.
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Further, the diagnostic performance of the two cutoffs were illustrated using sensitivity (SN), SP, positive predictive value (PPV), negative predictive value (NPV), and the odds ratio (OR). The low‐stringency cutoff (\>0.59) yielded PPV and NPV values of 0.70 and 0.89 (Fig. [3](#hep30572-fig-0003){ref-type="fig"}B), respectively, whereas the stringent cutoff (\>0.68) resulted in a PPV of 0.83 with an NPV of 0.85 (Fig. [3](#hep30572-fig-0003){ref-type="fig"}B), indicating that 83% of patients who tested positive suffered from postoperative LD, whereas 85% of patients who tested negative did not suffer from postoperative LD. The ORs for an adverse event were 18.66 (*P* \< 0.0001) and 19.7 (*P* \< 0.0001) for the two cutoffs, respectively. ROC curve analysis was performed for the miRNA model and compared with ROC curves of standard liver function parameters (Fig. [3](#hep30572-fig-0003){ref-type="fig"}B). We observed an AUC of 0.77 for the miRNA model, which exceeded the AUC of other parameters, including indocyanine green (ICG) plasma disappearance and retention rates as well as standard blood parameters like alanine transaminase (ALT), aspartate transaminase (AST), and gamma‐glutamyl transpeptidase (GGT). Further, we compared SN, SP, NPV, and PPV in a subset of patients who also had preoperative volumetric analyses (N = 33). miRNA pairs were found to identify patients subsequently suffering from postoperative LD with a higher predictive potential as compared with ICG clearance, but also exceeded the predictive potential of volumetric analyses (cutoff of 30% future liver remnant), as illustrated in Supporting Table [S4](#hep30572-sup-0001){ref-type="supplementary-material"}. Finally, ORs for other adverse postoperative outcomes were analyzed for both cut‐off models. ORs for severe morbidity reached significance for both cutoffs (Fig. [3](#hep30572-fig-0003){ref-type="fig"}C). Although OR for mortality was found to be significant for the low‐stringency cutoff, the high‐stringency cutoff was not significant but showed a comparable tendency (Fig. [3](#hep30572-fig-0003){ref-type="fig"}D). Further, patients fulfilling our cutoffs were found to stay significantly longer on the intensive care unit (ICU) and remained hospitalized for a prolonged time (Fig. [3](#hep30572-fig-0003){ref-type="fig"}E,F).

miRNA Pairs Represent Significant Predictors of Postoperative Outcome in the Respective Tumor Types {#hep30572-sec-0014}
---------------------------------------------------------------------------------------------------

As the underlying tumor entity is a known confounding factor for the analysis of postoperative outcomes in this patient cohort, further subgroup analyses were computed. Accordingly, patients were divided into the three largest subgroups---mCRC (n = 56), HCC (n = 46), and CCC (n = 41)---and were analyzed separately (Fig. [4](#hep30572-fig-0004){ref-type="fig"}A‐C). Indeed, the preoperative miRNA signature was found to differ significantly between patients with and without postoperative LD for each tumor type. Further, ROC analysis revealed comparably good predictive potentials. Lastly, evaluation of the proposed cutoffs for prediction of LD showed a strong predictive potential, irrespective of tumor entity. (Fig. [4](#hep30572-fig-0004){ref-type="fig"}A‐C).

![Tumor‐specific subgroup analyses of miRNA predictive potential for postoperative LD. Distribution of the combined ratio (miR151a‐5p/192‐5p//miR122‐5p/151a‐5p), ROC curves for an LR model (the performance is described by the AUC and whether the classification deviates significantly from the random assignment \[AUC = 0.5\] is indicated by the *P* value), and the percentage of true postoperative LD on predicted controls and predicted LD with respect to both model‐defined cutoffs (*P* \> 0.59 and *P* \> 0.68) are illustrated for the subgroups of patients with mCRC (A), HCC (B), and CCC (C), respectively.](HEP-69-2636-g004){#hep30572-fig-0004}

Discovered miRNA Ratios Allow Dynamical Monitoring of Liver Function Recovery After Liver Resection and Might Enable Identification of an Optimized Time Point for Operation {#hep30572-sec-0015}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we aimed to determine dynamical changes of miRNA pairs after operation to evaluate their association with liver function. Accordingly, miRNA ratios were assessed preoperatively (pre‐OP) as well as on POD 1 and POD 5 in a matched cohort of patients with regular major liver resection (n = 7) and patients undergoing the ALPPS procedure (n = 8, see details on the procedure in Fig. [5](#hep30572-fig-0005){ref-type="fig"}A and below). Basic characteristics are illustrated in Supporting Table [S2](#hep30572-sup-0001){ref-type="supplementary-material"}. Although miRNA pairs as well as the combined LD probability changed significantly after liver resection (POD 1 vs. pre‐OP) in all patients to a comparable level, most of them recovered until POD 5 in parallel with a regular liver function recovery.

As timing of the second stage of the ALPPS procedure is still a challenge for clinicians, the usefulness of miRNA pairs for this task was evaluated. Interestingly, patients undergoing the ALPPS procedure were found to display unaltered miRNA ratios after the second step of the procedure (regeneration grossly completed), whereas they behaved similarly to patients undergoing regular liver resection after the first step of the procedure (Fig. [5](#hep30572-fig-0005){ref-type="fig"}C). Of note, all patients who developed postoperative LD after the second step of the ALPPS procedure showed a worsened pattern of miRNA profile when compared with the remaining patients (*P* = 0.054, Fig. [5](#hep30572-fig-0005){ref-type="fig"}D). More importantly, the 2 patients with highest detected miRNA ratios before the second operation died after the second step of the procedure (Fig. [5](#hep30572-fig-0005){ref-type="fig"}D), indicating that the miRNA ratios are indeed predictive of functional liver recovery.

![miRNA pairs follow liver function recovery after partial hepatectomy and predict postoperative LD after the second step of ALPPS. Panel (A) illustrates the study design of this additional exploratory study as well as summarizes the procedural algorithm of ALPPS. The ALPPS procedure was described by Schnitzbauer et al. and has been developed to allow for rapid liver regeneration in borderline‐resectable patients with an insufficient liver remnant.[50](#hep30572-bib-0050){ref-type="ref"} Briefly, during the first step of the ALPPS procedure, the portal vein branch, feeding the tumor‐bearing liver lobe, is selectively ligated, whereas the arterial as well as bile structures are preserved and the liver parenchyma is further transected during this initial step of operation. This procedure leads to an improved liver regeneration within the time frame of days. Still, after this substantial gain of liver regeneration, a second surgical procedure has to be performed in which the ligated remaining liver lobes need to be removed. Perioperative dynamics of miRNAs were evaluated in a group of 7 patients with regular partial hepatectomy and 8 patients undergoing ALPPS (details are listed in Supporting Table [S2](#hep30572-sup-0001){ref-type="supplementary-material"}) for which longitudinal measurement of miRNAs could be performed on the basis of repeatedly collected plasma samples. Time points of blood collection are given in (A). Perioperative dynamics of miRNA pairs as well as combined pairs are illustrated in (B) (POD 1 vs. pre‐OP, 151a‐5p_192‐5p, ALPPS, *P* = 0.012, regular major liver resection, *P* = 0.018; 122‐5p_151a‐5p, ALPPS, *P* = 0.012, regular major liver resection, *P* = 0.018, 122‐5p_151a‐5p II 151a‐5p_192‐5p, ALPPS, *P* = 0.012, regular major liver resection, *P* = 0.018; POD 5 vs. POD 1, 151a‐5p_192‐5p, ALPPS, *P* = 0.018, regular major liver resection, *P* = 0.018; 122‐5p_151a‐5p, ALPPS, *P* = 0.018, regular major liver resection, *P* = 0.018, 122‐5p_151a‐5p II 151a‐5p_192‐5p, ALPPS, *P* = 0.018, regular major liver resection, *P* = 0.018). As during the second step of ALPPS, only the atrophic liver lobe is removed; we further analyzed miRNA pairs after the second step of ALPPS as illustrated in (C), showing an almost vanished increase in miRNA ratios after this second operation. Ultimately, (D) illustrates the predictive potential of the combined miRNA pairs before the second step of ALPPS as stratified according to postoperative LD and mortality after the removal of the atrophic lobe. \**P* \< 0.05, \*\**P* \< 0.005.](HEP-69-2636-g005){#hep30572-fig-0005}

Discussion {#hep30572-sec-0016}
==========

Using NGS as an unbiased systematic approach, we were able to detect 554 miRNAs in the plasma of patients before liver resection. Of those, a signature was identified---consisting of three miRNAs 151a‐5p, 192‐5p, and 122‐5p---that specifically detected, before the operation, the patients who developed postoperative LD. In particular, an LR model of the two miRNA ratios 151a‐5p/192‐5p and 122‐5p/151a‐5p reliably predicted postoperative LD, severe morbidity, prolonged ICU as well as hospital stay, and even mortality before the operation with a remarkable accuracy. Of note, multivariate LR of the entire cohort found both miRNA ratios to be independent predictors of postoperative LD (study design summarized in Fig. [6](#hep30572-fig-0006){ref-type="fig"}). Given the clinical relevance of predicting potentially fatal postoperative clinical outcomes after liver resection, our data demonstrate the clinical utility of an miRNA‐based biomarker to support the selection of patients undergoing partial hepatectomy.

![Study overview. In the discovery phase, plasma of 48 patients (21 with LD matched with 27 patients without LD after liver resection) was analyzed before operation to determine if miRNA signatures can serve as predictive markers. Using RNA sequencing, 19 microRNAs of interest were discovered and subjected to qPCR confirmation. In‐depth analysis predicted a marker potential for the miRNA pairs miR‐122‐5p/miR151a and miR‐151a/miR192‐5p (silver box). In the validation phase, the two miRNA pairs were reevaluated in an independent cohort consisting of 98 patients (8 with LD and 90 without LD after liver resection) (golden box). For performance evaluation, the combined data set was used to evaluate SN, SP, PPV, NPV, and ORs and compare them to previously used clinical markers (platinum box).](HEP-69-2636-g006){#hep30572-fig-0006}

Specifically in early stages of liver disease, clinical evaluation and quantification of liver function remains challenging. However, even slightly diminished liver function can be of major relevance if certain stressors, such as extensive liver resection, come into play. Although several tests have been developed, only a few have found their way into routine clinical application. Major drawbacks of available predictors are availability, high costs, and invasiveness.[19](#hep30572-bib-0019){ref-type="ref"} Although hepatic venous pressure gradient predicts postoperative clinical outcomes in HCC patients,[20](#hep30572-bib-0020){ref-type="ref"}, [21](#hep30572-bib-0021){ref-type="ref"}, [22](#hep30572-bib-0022){ref-type="ref"} it remains reserved for high‐risk patients because of its invasiveness. Other less invasive and well‐established markers to assess liver function rely on dynamic functional assessment of the liver. In this context, multiple groups have documented that ICG clearance is vital to predict postoperative LD and morbidity.[23](#hep30572-bib-0023){ref-type="ref"} However, we here document that miRNA signatures outperform ICG in terms of diagnostic accuracy by far. Furthermore, miRNA signatures even exceeded volumetric analyses in terms of prediction of postoperative LD (see Supporting Table [S4](#hep30572-sup-0001){ref-type="supplementary-material"}).

Despite using an unbiased approach, the miRNAs predicting LD all have very distinct roles in liver (patho)physiology and therefore could potentially serve not only as predictive markers but also as therapeutic targets. Although various miRNAs regulate liver functions in health and disease,[24](#hep30572-bib-0024){ref-type="ref"} miRNA‐122 is the most prominent one, as it constitutes 70% of miRNA copies in hepatocytes.[25](#hep30572-bib-0025){ref-type="ref"}, [26](#hep30572-bib-0026){ref-type="ref"} Altered miRNA‐122 expression has been implicated in a variety of liver diseases, including viral hepatitis, alcohol‐induced liver disease, nonalcoholic fatty liver disease, and HCC,[27](#hep30572-bib-0027){ref-type="ref"}, [28](#hep30572-bib-0028){ref-type="ref"}, [29](#hep30572-bib-0029){ref-type="ref"}, [30](#hep30572-bib-0030){ref-type="ref"}, [31](#hep30572-bib-0031){ref-type="ref"} reflecting its critical and pleiotropic role in regulating liver function. Specifically, miRNA‐122 negatively controls the expression of genes involved in cell cycle--associated processes, hepatic metabolism, and extracellular matrix receptor interactions,[32](#hep30572-bib-0032){ref-type="ref"}, [33](#hep30572-bib-0033){ref-type="ref"}, [34](#hep30572-bib-0034){ref-type="ref"}, [35](#hep30572-bib-0035){ref-type="ref"} all of which may contribute to liver regeneration. Furthermore, circulating levels of miRNA‐122 are considered as an early and sensitive biomarker for liver injury,[36](#hep30572-bib-0036){ref-type="ref"}, [37](#hep30572-bib-0037){ref-type="ref"}, [38](#hep30572-bib-0038){ref-type="ref"} and pharmacological inhibition or genetic depletion of miRNA‐122 affects hepatocyte differentiation and spontaneous progression to fibrosis and carcinogenesis.[27](#hep30572-bib-0027){ref-type="ref"}, [39](#hep30572-bib-0039){ref-type="ref"}

Aside from miRNA‐122, miRNA‐192 was also enriched in liver tissue. Further, blood levels have been reported to correlate with the histopathology of liver degeneration and HCC.[31](#hep30572-bib-0031){ref-type="ref"} However, aside from its direct marker potential, miRNA‐192 might influence liver regeneration through its antiangiogenic properties, as it has been shown on delivery in various tumor models by targeting two key transcription factors, early growth response 1 and homeobox B9.[40](#hep30572-bib-0040){ref-type="ref"} These transcription factors further promote the expression of several angiogenic factors.[40](#hep30572-bib-0040){ref-type="ref"}, [41](#hep30572-bib-0041){ref-type="ref"}, [42](#hep30572-bib-0042){ref-type="ref"}, [43](#hep30572-bib-0043){ref-type="ref"}, [44](#hep30572-bib-0044){ref-type="ref"}, [45](#hep30572-bib-0045){ref-type="ref"}

Ultimately, miRNA‐151 has also recently been identified as an oncogenic miRNA in HCC, in which increased levels in patients correlated with poor prognosis. It has been suggested that miRNA‐151 promotes metastasis in liver cancer in synergy with its host gene, focal adhesion kinase, through down‐regulating the metastasis suppressor Rho guanosine diphosphate dissociation inhibitor alpha and thereby inducing Rac family small, cell division cycle 42, and Rho guanosine triphosphatases.[46](#hep30572-bib-0046){ref-type="ref"} Furthermore, in lung cancer, miRNA‐151a has been reported to target E‐cadherin and promote cell proliferation and motility of cancer cells, while not affecting normal lung endothelial growth,[47](#hep30572-bib-0047){ref-type="ref"} suggesting a pro‐proliferative effect of miRNA‐151a. In summary, the existing data on physiologic interactions of the selected miRNAs suggest an additional deleterious effect on liver regeneration, next to its highly sensitive prognostic potential for LD. If miRNAs are setting the scene for sufficient liver regeneration, they might also represent an attractive therapeutic target. However, this aspect will need more detailed evaluation.

It should be pointed out that we used miRNA pairs to allow for self‐normalization of circulating plasma miRNAs. This is important because robust endogenous references, which are commonly applied for normalization of cell‐based or tissue‐based expression data, are not available for plasma. Therefore, Sheinerman et al. introduced the concept of "self‐normalizing" miRNA pairs (i.e., the combination of two miRNAs) to improve both the robustness and performance of miRNA biomarkers.[48](#hep30572-bib-0048){ref-type="ref"}, [49](#hep30572-bib-0049){ref-type="ref"} This self‐normalization of miRNAs was essential to allow for the precise prediction of postoperative outcome after liver resection, which was not achieved by individual miRNAs.

Of note, perioperative time course of miRNA pairs was also evaluated in an additional exploratory study. As an acute reaction to the operative trauma (on POD 1), miRNA pairs worsen excessively in all patients. However, as liver function recovers after operation, miRNA pairs seem to closely follow and normalized in most patients until POD 5. In this context, the data of the ALPPS model are of specific interest. miRNA pairs significantly worsened after the first step of this operation, which comprises the main part of tissue destruction. Intriguingly however, there was almost no dynamic in the level of the evaluated miRNA ratios after accomplishment of the second step, when the atrophic liver lobe was removed. This parallels the regeneratory pattern of the ALPPS procedure, which consists of augmented induction after step 1 and only little alternation after the second operation. Hence, the analyzed miRNA pairs seem to reflect liver function and its recovery. Notably, these data show a fast adaptation of miRNA profiles in accordance with the clinical setting, indicating that the proposed miRNA‐based marker represents a dynamic tool for estimation of hepatic reserve. However, these data are only of exploratory nature and have to be validated in larger cohorts. The analyses of miRNA pairs in the ALPPS model allowed for generation of the presumably most interesting and clinically relevant data of this manuscript. In particular, we observed that patients who did not recover after the first step of ALPPS in terms of combined miRNA pairs were indeed those who developed very poorly after the second step of ALPPS. Indeed, all 3 patients who suffered from LD after the second step had the highest miRNA pair values before the second step. More importantly, the 2 patients who died as a result of small‐for‐size syndrome showed the highest values of miRNA ratios. These exploratory data are highly indicative of the crucial relevance of miRNA in dynamically monitoring liver function and in potentially determining the optimal time point for liver resection. This could also be relevant for patients treated with portal vein embolization/ligation or following extensive neoadjuvant chemotherapy.

Taken together, the data indicate that this marker could help to provide an improved strategy to identify patients who will not benefit from operation or may even suffer from potentially lethal complications. Thereby, our data should help to tailor surgical strategies to the specific risk profile of individual patients in an easy, cost‐effective, and noninvasive manner. This could pave the way to personalizing liver operation in patients with liver tumors, thereby increasing therapeutic effectiveness and the quality of a patient\'s life and dramatically reducing health care costs.
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